-
Product Insights
Abacus Ppty/ Charter Hall – 201 Elizabeth Street Podium Expansion – New South Wales
Equip yourself with the essential tools needed to make informed and profitable decisions with our Abacus Ppty/ Charter Hall - 201 Elizabeth Street Podium Expansion - New South Wales report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the...
-
Product Insights
Bridge Unv/ Global City Invt/ Podium Dev Corp/ RER Finl – The One at University City – Florida
Equip yourself with the essential tools needed to make informed and profitable decisions with our Bridge Unv/ Global City Invt/ Podium Dev Corp/ RER Finl - The One at University City - Florida report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose...
-
Company Profile
Lendlease Corp Ltd – Company Profile
Lendlease Corp Ltd (Lendlease) is a provider of real estate services. It designs, develops, and constructs; and owns, operates, and manages property and infrastructure assets. The company offers asset and property management, building, construction, consultancy, development management, engineering, infrastructure development, investment management, and project management services. Lendlease also provides financial services and co-invests in various projects. Its Lendlease Digital and Lendlease Podium businesses focus at simplifying complex interdependencies in the built world. The company executes residential, commercial office, government, healthcare,...
Add to Basket -
Product Insights
Gouty Arthritis (Gout) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in the blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area, and joint redness. Risk factors include obesity, high alcohol intake, injury to joints, long-standing kidney disease, and high intake of foods rich in purines. The Gouty Arthritis (Gout)...
-
Product Insights
3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
3 Phosphoinositide Dependent Protein Kinase 1 is an enzyme encoded by the PDPK1 gene, which plays a central role in the transduction of signals from insulin by providing the activating phosphorylation to PKB/AKT1, thus propagating the signal to downstream targets controlling cell proliferation and survival, as well as glucose and amino acid uptake and storage. It negatively regulates the TGF-beta-induced signaling by modulating the association of SMAD3 and SMAD7 with TGF-beta receptor, phosphorylating SMAD2, SMAD3, SMAD4 and SMAD7, preventing the...
-
Product Insights
Glabellar Rhytides Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Glabellar Rhytides Global Clinical Trials Review, H1, 2016" provides an overview of Glabellar Rhytides clinical trials scenario. This report provides top line data relating to the clinical trials on Glabellar Rhytides. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
UK Mortgage Market 2019: Forecasts and Future Opportunities to 2023
The outlook for the residential mortgage market remained fairly neutral in 2019. Growth in gross mortgage lending is expected to be around 4.5% in 2020, which is broadly unchanged on 2019. During the forecast period (2019-23), gross advances are expected to record a compound annual growth rate of 5%, reaching £339bn. The supply side has been positively affected by the government’s schemes supporting first-time buyers, while stricter controls on buy-to-let lending will improve matters by reducing investor demand for properties....